You searched for "infection"
Insects, swelling and sight loss: a case of orbital inflammatory syndrome
1 June 2022
| Parushak Rezai, Susan Sarangapani
|
EYE - General
Despite being the most common cause of painful orbital mass in adults and the third most common orbital disease, orbital inflammatory syndrome still proves to be a difficult ocular condition to diagnose, treat, and manage. A 41-year-old lady presented to...
PACK-crosslinking for infectious keratitis
1 October 2015
| David Tabibian, Farhad Hafezi
|
EYE - Cornea
Corneal cross-linking with riboflavin and UV-A light (CXL) is a technology that has been initially developed to treat corneal ectatic disorders [1]. Its effect in stabilising diseases such as keratoconus was reported in numerous trials with excellent long-term outcomes and...
Extraocular muscle OCT
The goal was to evaluate the use of the Heidelberg anterior segment optical coherence tomography (AS-OCT) to image extraocular rectus muscle insertions and to expand the use of the AS-OCT to also image vertical rectus muscles. The authors evaluated inter...New solutions in the prevention and treatment of Acanthamoeba keratitis
5 October 2020
| Ronnie Mooney, Roderick Williams, Fiona Henriquez (Prof)
|
EYE - Cornea, EYE - General
The global increase in Acanthamoeba keratitis infections has emphasised the inefficiencies of current treatment and preventative methods, here researchers from the West of Scotland detail a promising new series of compounds that may stem the tide. News headlines detailing horror...
Can intravitreal anti-VEGF injections affect corneal nerves?
This was a retrospective case-control study looking at the effect of anti-VEGF injections on corneal nerves (CN). Fifty-seven patients with a history of at least three anti-VEGF injections in one or both eyes and available confocal microscopic imaging were included...
Outcomes of reinjection of Ranibizumab for reactivation of retinopathy of prematurity
The authors present their data from Egypt assessing the effects of Ranibizumab reinjection for neonates with retinopathy of prematurity (ROP). Doses given were 0.25mg/0.025mL. They screened 2318 infants with 115 (5%) of infants with a mean post menstrual age (PMA)...
Extraocular muscle BT after ocular pathology
Management is described for 13 patients who received inferior rectus botulinum toxin (BT) injection for vertical strabismus due to orbital pathology. Patients were aged 19-86 years, eight were female and seven were right eye injections. Orbital pathology included six with...
Intravitreal injection related endophthalmitis
1 April 2015
| Jaya Myneni
|
EYE - Vitreo-Retinal
This article reviews the incidence, clinical findings, risk factors, management and visual outcomes in intravitreal injection related endophthalmitis. Incidence of this complication is reported to be in the range of 0.038% to 0.065% (1 in 2000-3000 injections). Patients present typically...
The ocular manifestations of COVID-19: an overview of current literature
Although respiratory symptoms are the most frequent manifestation of COVID-19, multi-organ involvement has been demonstrated, including ocular manifestations. The author investigates how the eye can be affected. The SARS-CoV-2 virus responsible for the COVID-19 pandemic has presented a significant public...
Postoperative diplopia test with BT for inferior oblique overaction
The authors evaluate a novel assessment of botulinum toxin (BT) injection into the inferior oblique (IO) as a postoperative test in those with secondary IO overaction. This was a retrospective review of 23 injections for 18 patients using 1.25U of...Orbital cellulitis - an overview of the diagnosis and management
1 February 2022
| Mohammad Farwana
|
EYE - Orbit, EYE - Neuro-ophthalmology, EYE - Imaging, EYE - General
Periorbital (preseptal) and orbital cellulitis are infections of the subcutaneous tissues of the eye. They are differentiated by the location of the infection. Periorbital cellulitis refers to infection of the eyelid and subcutaneous tissues anterior to the orbital septum, whereas...
Adjuvant intravitreal dexamethasone implant for persistent CME
1 October 2019
| Sofia Rokerya
|
EYE - Vitreo-Retinal
In this retrospective, cross-sectional study the authors investigate the efficiency of intravitreal dexamethasone implants (0.7mg) for cystoid macular oedema (CME) persisting, despite immunomodulatory treatment in patients with Behcets’ disease (BD). Twenty-seven eyes of 20 patients (12 males and eight females)...
